IκB/IKK

シグナル伝達経路

研究分野

阻害剤の選択性比較

カタログ番号	製品カタログ	溶解度(25°C)
カタログ番号	製品カタログ	水	DMSO	アルコール
S1274	BX-795	<1 mg/mL	100 mg/mL	<1 mg/mL
S2913	BAY 11-7082	<1 mg/mL	41 mg/mL	10 mg/mL
S2882	IKK-16 (IKK Inhibitor VII)	<1 mg/mL	97 mg/mL	''<1 mg/mL
S2824	TPCA-1	<1 mg/mL	56 mg/mL	<1 mg/mL
S2864	IMD 0354	<1 mg/mL	10 mg/mL	77 mg/mL
S8922	TBK1/IKKε-IN-1(compound 1)	˂1 mg/mL	10 mg/mL	˂1 mg/mL
S0425	TBK1/IKKε-IN-2	<1 mg/mL	60 mg/mL	''<1 mg/mL
S8872	GSK8612	<1 mg/mL	100 mg/mL	6 mg/mL
S8078	Bardoxolone Methyl	<1 mg/mL	21 mg/mL	''<1 mg/mL
S8044	BMS-345541	<1 mg/mL	9 mg/mL	<1 mg/mL
S4907	SC-514	<1 mg/mL	45 mg/mL	<1 mg/mL
S1681	Mesalamine	<1 mg/mL	31 mg/mL	31 mg/mL
S7352	Bay 11-7085	<1 mg/mL	50 mg/mL	50 mg/mL
S3615	Dehydrocostus Lactone	<1 mg/mL	46 mg/mL	46 mg/mL
S7851	AZD3264	<1 mg/mL	88 mg/mL	2 mg/mL
S7697	LY2409881	<1 mg/mL	20 mg/mL	<1 mg/mL
S7691	PS-1145	<1 mg/mL	64 mg/mL	2 mg/mL
S7948	MRT67307 HCl	92 mg/mL	92 mg/mL	92 mg/mL
S9042	Wedelolactone	-1 mg/mL	63 mg/mL	-1 mg/mL
S3612	Rosmarinic acid	24 mg/mL	72 mg/mL	72 mg/mL
S7441	WS3	<1 mg/mL	100 mg/mL	80 mg/mL
S7442	WS6	<1 mg/mL	100 mg/mL	100 mg/mL

亜型選択性的な製品

IκB/IKK製品

All (24) IκB/IKK阻害剤(22) IκB/IKKモジュレータ(2)

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1274	BX-795 BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.	J Thromb Haemost, 2020, 10.1111/jth.14748 Nature, 2019, 567(7747):262-266 Cell, 2019, 176(6):1447-1460	Induction of basal p62 Ser403 phosphorylation in ULK1/2-deﬁcient MEF was suppressed by BX-795, an inhibitor of TBK1. WT ( Ulk1 +/+/Ulk2 +/+) and Ulk1 -/- /Ulk2 -/-(KO) MEF were treated with NaCl/Pi (Con) or 10 uM BX-795 for 6 h, and subjected to immunoblotting with indicated antibodies.
S2913	BAY 11-7082 BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.	Nat Commun, 2020, 19;11(1):2487 Sci Adv, 2020, 26;6(9):eaay9269 Cell Rep, 2020, 5;31(5):107585	Immunofluorescence images of Ishikawa cells showing the increase in the nuclear colocalization of ERa (red) and p65 (green) after E2 incubation. Nuclear colocalization is yellow. Treatment with ICI 182,780, PDTC or Bay inhibited the nuclear localization of both ERa and p65. Blue, DAPI-stained nuclei. All pictures were obtained the same day using the same microscope settings. Original magnification 3200, bar =50 um. Arrows, cytoplasmic ERa and p65 staining. ICI, ICI 182,780; Bay, Bay 11-7082.
S2882	IKK-16 (IKK Inhibitor VII) IKK-16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM in cell-free assays, respectively. IKK-16 also inhibits LRRK2 Ser935 phosphorylation in cells and LRRK2 kinase activity in vitro with IC50 of 50 nM.	EMBO J, 2020, 1;39(7):e103304 Cell Rep, 2020, 30(10):3383-3396 Cell Mol Neurobiol, 2020, 18	Reduction in IFN-g production in TcREG by IKK-16 coincides with decrease in T-bet and Eomes expression levels. Flow cytometry plots showing cellular analysis for T-bet and Eomes in CD45+CD3+CD8+ population.
S2824	TPCA-1 TPCA-1 is an inhibitor of IKK-2 with IC50 of 17.9 nM in a cell-free assay, inhibits NF-κB pathway, exhibits 22-fold selectivity over IKK-1.	Cell Death Dis, 2020, 24;11(4):282 Cells, 2020, 9(2) Eur J Pharmacol, 2020, 873:172981	AGS cells were treated with cwith IL-1β in the presence of the IKK inhibitor TPCA-1, the p38 MAPK inhibitor BIX02188 and the JNK inhibitor SP600125. Cell lysates were obtained 24 h after IL-1β treatment and immunoblotted with PTEN antibodies.
S2864	IMD 0354 IMD-0354 is an IKKβ inhibitor and blocks IκBα phosphorylation in NF-κB pathway.	J Allergy Clin Immunol, 2020, 145(1):437-440 Mucosal Immunol, 2020, 13(1):86-95 Hepatology, 2020, 10.1002	(B) Histological examinations of xenograft lesions produced by A549 cells. We stained the lesions with H&E, TUNEL and staining for Ki-67. (C, D) The histogram shows percentage of A549 cells that were positive for proliferation marker Ki-67 and apoptosis marker TUNEL in 3 representative fields. Results are expressed as the mean ± SD. ns. P > 0.05, P < 0.01 and *P < 0.001 for the indicated comparisons by 1-way A OVA or Student’s t test.
S8922^新	TBK1/IKKε-IN-1(compound 1) TBK1/IKKε-IN-1 (compound 1) is a dual inhibitor of TANK-binding kinase 1 (TBK1) and IκB kinase-ε (IKKε/IKK-i) with IC50 of 1.0 nM and 5.6 nM for TBK1 and IKKε, respectively. TBK1/IKKε inhibition enhances response to PD-1 blockade, which effectively predicts tumor response in vivo.
S0425^新	TBK1/IKKε-IN-2 TBK1/IKKε-IN-2 is a dual inhibitor of TBK1 and IKKε.
S8935^新	BAY-985 BAY-985 is a potent and highly selective TBK1/IKKε inhibitor. BAY-985 shows high potency toward TBK1 (IC50 = 2 nM, low ATP assay; 30 nM, high ATP assay) and IKKε(IC50 = 2 nM), as well as high potency in the mechanistic pIRF3 assay (IC50 = 74 nM), and an antiproliferative effect on SK-MEL-2 cells (IC50 = 900 nM).
S6714^新	INH14 INH14 is an inhibitor of TLR2-mediated NF-kB activation with IC50 values of 8.975 μM and 3.598 μM for IKKα and IKKβ, respectively.
S8872^新	GSK8612 GSK8612 is a highly potent and selective inhibitor for TBK1 (Tank-binding Kinase-1) with pKd of 8.0. Within 10-fold affinity with respect to TBK1, no off-targets of GSK8612 could be identified.
S8078	Bardoxolone Methyl Bardoxolone Methyl is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor.	Antioxidants (Basel), 2020, 9(1) Radiat Environ Biophys, 2020, 14 Free Radic Biol Med, 2019, 138:33-42	Renal Nrf2 activity was shown in RTA402-treated acFSGS (RTA402 + acFSGS) mice as early as day 7 (RTA402 + acFSGS) and persisted to day 28, compared to vehicle + acFSGS mice. Kidney in situ ROS production demonstrated by DHE detection.
S8044	BMS-345541 BMS-345541 is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM in cell-free assays, respectively.	Nature, 2020, 579(7798):284-290 Nat Commun, 2020, 27;11(1):2042 Biochem Pharmacol, 2020, 12:114023	(E) After transfection with control or catalase siRNAs for 24 h, A375 and G361 cells were treated with vehicle or 2.5 µM BMS-345541, 20 µM PS-1145 and/or 50 µM of fotemustine for an additional 48 h. Cell viability was then assessed. , p<0.05. (F) A375 and G361 cells were treated with vehicle or 2.5 µM BMS-345541, 20 µM PS-1145 and/or 50 µM of fotemustine, in the presence or absence of catalase inhibitor 3-Amino-1,2,4-triazole (ATZ, 50 µM) for 48 h. Cell viability was then assessed. , p<0.05.
S4907	SC-514 SC-514 is an orally active, ATP-competitive IKK-2 inhibitor with IC50 of 3-12 μM, blocks NF-κB-dependent gene expression, does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.	Hepatology, 2020, 10.1002/hep.31249 J Immunol, 2020, 20 pii: ji1901089 Cell Signal, 2019, 55:17-25
S1681	Mesalamine Mesalamine is a specific inhibitor of TNFα-induced IKK activity, used to treat inflammatory bowel disease.
S7352	Bay 11-7085 BAY 11-7085 is an irreversible inhibitor of TNFα-induced IκBα phosphorylation with IC50 of 10 μM.	Cells, 2020, 9(2) Eur J Pharmacol, 2020, 873:172981 Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013	VSMCs were pretreated with BAY 11-7085 (BAY, 10μmol/L) for 1h and further treated with or without 10^-7mol/L salusin-β for 30min. A, Cytoplasmic extracts (Cy) were obtained and the phosphorylated IκBα, IκBα and HDCA3 protein levels were measured by western blot analysis. B, nuclear extracts (Nu) were obtained and the nuclear p50, p65 and HDAC3 protein levels were measured by western blot analysis. Data are expressed as means ± SD (n=3). *P< 0.05 versus the control with no treatment; #P< 0.05 versus 10^-7mol/L salusin-β treatment alone.
S3615	Dehydrocostus Lactone Dehydrocostus lactone (DHE), a natural sesquiterpene lactone, inhibits IKKβ activity, IκBα phosphorylation and degradation, coactivators p300 recruitments and p50/p65 NF-κB nuclear translocation, and their DNA binding activity on COX-2 promoter. It has anti-inflammatory, anti-ulcer, immunomodulatory and anti-tumor properties.	Int Immunopharmacol, 2020, 78:106075 J Cell Mol Med, 2019, 23(8):5762-5770
S7851	AZD3264 AZD3264 is a novel IKK2 inhibitor.	Redox Biol, 2017, 11:562-576	(C) G361 cells were loaded with DCF (ROS probe) and further stimulated with vehicle or indicated IKKβ inhibitors for 3 h. Fluorescence was measured using a fluorescence microplate reader. *, p<0.05 versus control.
S7697	LY2409881 LY2409881 is a potent and selective IKK2 inhibitor with IC50 of 30 nM, >10-fold selectivity over IKK1 and other common kinases.	Nat Commun, 2019, 10(1):2924 Mol Pharm, 2018, 15(2):609-618 J Biol Chem, 2018, 293(30):11913-11927	A549 cells were treated with NF-kB inhibitor LY2409881 (30 nM) for 2 h, followed by western blot analysis of p-NF-kB.
S7691	PS-1145 PS-1145 is a specific IKK inhibitor with IC50 of 88 nM.	J Biol Chem, 2018, 293(19):7268-7280 Redox Biol, 2017, 562-576 Blood, 2016, 128(1):82-92	(E) After transfection with control or catalase siRNAs for 24 h, A375 and G361 cells were treated with vehicle or 2.5 µM BMS-345541, 20 µM PS-1145 and/or 50 µM of fotemustine for an additional 48 h. Cell viability was then assessed. , p<0.05. (F) A375 and G361 cells were treated with vehicle or 2.5 µM BMS-345541, 20 µM PS-1145 and/or 50 µM of fotemustine, in the presence or absence of catalase inhibitor 3-Amino-1,2,4-triazole (ATZ, 50 µM) for 48 h. Cell viability was then assessed. , p<0.05.
S7948	MRT67307 HCl MRT67307 is a potent and dual IKKϵ and TBK1 inhibitor with IC50 of 160 and 19 nM, respectively.	Cancer Discov, 2020, 10(3):382-393 Mol Cell, 2019, 74(2):347-362.e6 Cell Death Differ, 2019, 26(6):1077-1088
S9042	Wedelolactone Wedelolactone, a medicinal plant-derived natural compound, is an inhibitor of IKK that is critical for activation of NF-κB by mediating phosphorylation and degradation of IκBα.	Int Immunopharmacol, 2019, 73:17-22
S3612	Rosmarinic acid Rosmarinic acid (RA) is a naturally occurring hydroxylated compound. It has the ability to block complement fixation, inhibit lipoxygenase and cyclooxygenase activity and inhibit the expression of CCL11 and CCR3 by suppressing the IKK-β activity in NF-κB activation signaling.
S7441	WS3 WS3 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
S7442	WS6 WS6 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S1274	BX-795 BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.	J Thromb Haemost, 2020, 10.1111/jth.14748 Nature, 2019, 567(7747):262-266 Cell, 2019, 176(6):1447-1460	Induction of basal p62 Ser403 phosphorylation in ULK1/2-deﬁcient MEF was suppressed by BX-795, an inhibitor of TBK1. WT ( Ulk1 +/+/Ulk2 +/+) and Ulk1 -/- /Ulk2 -/-(KO) MEF were treated with NaCl/Pi (Con) or 10 uM BX-795 for 6 h, and subjected to immunoblotting with indicated antibodies.
S2913	BAY 11-7082 BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.	Nat Commun, 2020, 19;11(1):2487 Sci Adv, 2020, 26;6(9):eaay9269 Cell Rep, 2020, 5;31(5):107585	Immunofluorescence images of Ishikawa cells showing the increase in the nuclear colocalization of ERa (red) and p65 (green) after E2 incubation. Nuclear colocalization is yellow. Treatment with ICI 182,780, PDTC or Bay inhibited the nuclear localization of both ERa and p65. Blue, DAPI-stained nuclei. All pictures were obtained the same day using the same microscope settings. Original magnification 3200, bar =50 um. Arrows, cytoplasmic ERa and p65 staining. ICI, ICI 182,780; Bay, Bay 11-7082.
S2882	IKK-16 (IKK Inhibitor VII) IKK-16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM in cell-free assays, respectively. IKK-16 also inhibits LRRK2 Ser935 phosphorylation in cells and LRRK2 kinase activity in vitro with IC50 of 50 nM.	EMBO J, 2020, 1;39(7):e103304 Cell Rep, 2020, 30(10):3383-3396 Cell Mol Neurobiol, 2020, 18	Reduction in IFN-g production in TcREG by IKK-16 coincides with decrease in T-bet and Eomes expression levels. Flow cytometry plots showing cellular analysis for T-bet and Eomes in CD45+CD3+CD8+ population.
S2824	TPCA-1 TPCA-1 is an inhibitor of IKK-2 with IC50 of 17.9 nM in a cell-free assay, inhibits NF-κB pathway, exhibits 22-fold selectivity over IKK-1.	Cell Death Dis, 2020, 24;11(4):282 Cells, 2020, 9(2) Eur J Pharmacol, 2020, 873:172981	AGS cells were treated with cwith IL-1β in the presence of the IKK inhibitor TPCA-1, the p38 MAPK inhibitor BIX02188 and the JNK inhibitor SP600125. Cell lysates were obtained 24 h after IL-1β treatment and immunoblotted with PTEN antibodies.
S2864	IMD 0354 IMD-0354 is an IKKβ inhibitor and blocks IκBα phosphorylation in NF-κB pathway.	J Allergy Clin Immunol, 2020, 145(1):437-440 Mucosal Immunol, 2020, 13(1):86-95 Hepatology, 2020, 10.1002	(B) Histological examinations of xenograft lesions produced by A549 cells. We stained the lesions with H&E, TUNEL and staining for Ki-67. (C, D) The histogram shows percentage of A549 cells that were positive for proliferation marker Ki-67 and apoptosis marker TUNEL in 3 representative fields. Results are expressed as the mean ± SD. ns. P > 0.05, P < 0.01 and *P < 0.001 for the indicated comparisons by 1-way A OVA or Student’s t test.
S8922^新	TBK1/IKKε-IN-1(compound 1) TBK1/IKKε-IN-1 (compound 1) is a dual inhibitor of TANK-binding kinase 1 (TBK1) and IκB kinase-ε (IKKε/IKK-i) with IC50 of 1.0 nM and 5.6 nM for TBK1 and IKKε, respectively. TBK1/IKKε inhibition enhances response to PD-1 blockade, which effectively predicts tumor response in vivo.
S0425^新	TBK1/IKKε-IN-2 TBK1/IKKε-IN-2 is a dual inhibitor of TBK1 and IKKε.
S8935^新	BAY-985 BAY-985 is a potent and highly selective TBK1/IKKε inhibitor. BAY-985 shows high potency toward TBK1 (IC50 = 2 nM, low ATP assay; 30 nM, high ATP assay) and IKKε(IC50 = 2 nM), as well as high potency in the mechanistic pIRF3 assay (IC50 = 74 nM), and an antiproliferative effect on SK-MEL-2 cells (IC50 = 900 nM).
S6714^新	INH14 INH14 is an inhibitor of TLR2-mediated NF-kB activation with IC50 values of 8.975 μM and 3.598 μM for IKKα and IKKβ, respectively.
S8872^新	GSK8612 GSK8612 is a highly potent and selective inhibitor for TBK1 (Tank-binding Kinase-1) with pKd of 8.0. Within 10-fold affinity with respect to TBK1, no off-targets of GSK8612 could be identified.
S8078	Bardoxolone Methyl Bardoxolone Methyl is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor.	Antioxidants (Basel), 2020, 9(1) Radiat Environ Biophys, 2020, 14 Free Radic Biol Med, 2019, 138:33-42	Renal Nrf2 activity was shown in RTA402-treated acFSGS (RTA402 + acFSGS) mice as early as day 7 (RTA402 + acFSGS) and persisted to day 28, compared to vehicle + acFSGS mice. Kidney in situ ROS production demonstrated by DHE detection.
S8044	BMS-345541 BMS-345541 is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM in cell-free assays, respectively.	Nature, 2020, 579(7798):284-290 Nat Commun, 2020, 27;11(1):2042 Biochem Pharmacol, 2020, 12:114023	(E) After transfection with control or catalase siRNAs for 24 h, A375 and G361 cells were treated with vehicle or 2.5 µM BMS-345541, 20 µM PS-1145 and/or 50 µM of fotemustine for an additional 48 h. Cell viability was then assessed. , p<0.05. (F) A375 and G361 cells were treated with vehicle or 2.5 µM BMS-345541, 20 µM PS-1145 and/or 50 µM of fotemustine, in the presence or absence of catalase inhibitor 3-Amino-1,2,4-triazole (ATZ, 50 µM) for 48 h. Cell viability was then assessed. , p<0.05.
S4907	SC-514 SC-514 is an orally active, ATP-competitive IKK-2 inhibitor with IC50 of 3-12 μM, blocks NF-κB-dependent gene expression, does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.	Hepatology, 2020, 10.1002/hep.31249 J Immunol, 2020, 20 pii: ji1901089 Cell Signal, 2019, 55:17-25
S1681	Mesalamine Mesalamine is a specific inhibitor of TNFα-induced IKK activity, used to treat inflammatory bowel disease.
S7352	Bay 11-7085 BAY 11-7085 is an irreversible inhibitor of TNFα-induced IκBα phosphorylation with IC50 of 10 μM.	Cells, 2020, 9(2) Eur J Pharmacol, 2020, 873:172981 Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013	VSMCs were pretreated with BAY 11-7085 (BAY, 10μmol/L) for 1h and further treated with or without 10^-7mol/L salusin-β for 30min. A, Cytoplasmic extracts (Cy) were obtained and the phosphorylated IκBα, IκBα and HDCA3 protein levels were measured by western blot analysis. B, nuclear extracts (Nu) were obtained and the nuclear p50, p65 and HDAC3 protein levels were measured by western blot analysis. Data are expressed as means ± SD (n=3). *P< 0.05 versus the control with no treatment; #P< 0.05 versus 10^-7mol/L salusin-β treatment alone.
S3615	Dehydrocostus Lactone Dehydrocostus lactone (DHE), a natural sesquiterpene lactone, inhibits IKKβ activity, IκBα phosphorylation and degradation, coactivators p300 recruitments and p50/p65 NF-κB nuclear translocation, and their DNA binding activity on COX-2 promoter. It has anti-inflammatory, anti-ulcer, immunomodulatory and anti-tumor properties.	Int Immunopharmacol, 2020, 78:106075 J Cell Mol Med, 2019, 23(8):5762-5770
S7851	AZD3264 AZD3264 is a novel IKK2 inhibitor.	Redox Biol, 2017, 11:562-576	(C) G361 cells were loaded with DCF (ROS probe) and further stimulated with vehicle or indicated IKKβ inhibitors for 3 h. Fluorescence was measured using a fluorescence microplate reader. *, p<0.05 versus control.
S7697	LY2409881 LY2409881 is a potent and selective IKK2 inhibitor with IC50 of 30 nM, >10-fold selectivity over IKK1 and other common kinases.	Nat Commun, 2019, 10(1):2924 Mol Pharm, 2018, 15(2):609-618 J Biol Chem, 2018, 293(30):11913-11927	A549 cells were treated with NF-kB inhibitor LY2409881 (30 nM) for 2 h, followed by western blot analysis of p-NF-kB.
S7691	PS-1145 PS-1145 is a specific IKK inhibitor with IC50 of 88 nM.	J Biol Chem, 2018, 293(19):7268-7280 Redox Biol, 2017, 562-576 Blood, 2016, 128(1):82-92	(E) After transfection with control or catalase siRNAs for 24 h, A375 and G361 cells were treated with vehicle or 2.5 µM BMS-345541, 20 µM PS-1145 and/or 50 µM of fotemustine for an additional 48 h. Cell viability was then assessed. , p<0.05. (F) A375 and G361 cells were treated with vehicle or 2.5 µM BMS-345541, 20 µM PS-1145 and/or 50 µM of fotemustine, in the presence or absence of catalase inhibitor 3-Amino-1,2,4-triazole (ATZ, 50 µM) for 48 h. Cell viability was then assessed. , p<0.05.
S7948	MRT67307 HCl MRT67307 is a potent and dual IKKϵ and TBK1 inhibitor with IC50 of 160 and 19 nM, respectively.	Cancer Discov, 2020, 10(3):382-393 Mol Cell, 2019, 74(2):347-362.e6 Cell Death Differ, 2019, 26(6):1077-1088
S9042	Wedelolactone Wedelolactone, a medicinal plant-derived natural compound, is an inhibitor of IKK that is critical for activation of NF-κB by mediating phosphorylation and degradation of IκBα.	Int Immunopharmacol, 2019, 73:17-22
S3612	Rosmarinic acid Rosmarinic acid (RA) is a naturally occurring hydroxylated compound. It has the ability to block complement fixation, inhibit lipoxygenase and cyclooxygenase activity and inhibit the expression of CCL11 and CCR3 by suppressing the IKK-β activity in NF-κB activation signaling.

製品コード	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S7441	WS3 WS3 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.
S7442	WS6 WS6 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.

製品コード

製品説明

文献中Selleckの製品使用例

お客様のフィードバック

S7441